Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Pure consciousness reveals a boundless reality beyond objects

When we are conscious, we are conscious of some thing: be it an object, a person, or an idea. But China-based philosopher Itay Shani argues that such “ordinary consciousness” is made possible by what he calls “pure consciousness”—a consciousness without objects, structure, boundaries, or form, which meditative and mystical traditions have long been aware of. Pure consciousness, Shani contends, is awareness of a boundless reality that no word or thought could ever capture, that can only be gestured at using negation, metaphor and contradiction. To recognize it is to recognize that there are worlds beyond our familiar world of objects and things.

When contemporary scientists and philosophers contemplate the question “What is consciousness?” they tend to do so by focusing on phenomenal states, namely, mental states endowed with a qualitative feel — a “what it’s like” character. When one is awake, aware, and fully in one’s senses, one is typically subject to a continuous stream of experiences involving rapidly unfolding trains of thoughts, feelings, and images, and accompanied by longer-lasting moods and emotional overtones.

Such phenomenal states feel a certain way. The sweet smell of the rose; the icy chill of a morning swim in the river; the tender pangs of longing — all are different from each other in terms of what it is like to have them. They are also, generally, directed at certain objects of thought, real or imaginary. A conscious experience is therefore said to be “of” or “about” something. There is something we think of when we think, something we perceive when we perceive, and so on. Moreover, these objects are presented in consciousness from a certain point of view—the perspective of the conscious subject. For example, objects are viewed from a particular angle, perceived as approaching or receding, as far or near, as surprising or familiar, and so on.

Leveraging traditional and advanced machine learning for comprehensive oncology data integration and outcome prediction

Outcome prediction in neuro-oncology remains challenging due to heterogeneity in tumor biology, imaging characteristics, treatment response, and patient-specific clinical factors. Although molecular databases have advanced understanding of brain tumor biology, many datasets lack broader data necessary for generalizable predictive modeling. Artificial intelligence (AI) and machine learning (ML) are increasingly being explored to integrate these heterogeneous data sources and support precision neuro-oncology.

A narrative review was performed using PubMed and Embase to identify studies evaluating oncology databases, ML models, multimodal data integration, and AI applications relevant to neuro-oncology. Studies published between 2020 and 2026 were preferentially reviewed, with additional landmark studies included when relevant.

Traditional ML approaches including regression-based models, random forests, support vector machines, and gradient boosting algorithms have been applied to survival prediction, recurrence classification, treatment response estimation, and molecular biomarker prediction using clinical, imaging, molecular, and population-level datasets. More advanced architectures including natural language processing, large language models, vision transformers, geometric deep learning, and graph neural networks have expanded the ability to analyze unstructured and multimodal data sources including radiology reports, histopathology slides, MRI volumes, molecular datasets, and electronic health records. Multimodal AI systems integrating imaging, molecular, histopathologic, clinical, and socioeconomic data frequently demonstrated improved predictive performance compared with single-modality models.

Address correspondence to: Michael C

Haffner, Fred Hutchinson Cancer Center, 1,100 Fairview Avenue N., E2-112, Seattle, Washington 98,109, USA. Phone: 206.667.6769; Email: [email protected]. Or to: Stephanie Harmon, NIH, 9,000 Rockville Pike, Building 41, Room A101-I, Bethesda, Maryland 20,892, USA. Phone: 240.858.3067; Email: [email protected]. Or to: Cora N. Sternberg, Englander Institute for Precision Medicine, Weill Cornell Medicine, Belfer Research Building, 413 East 69th Street, Room 1,412, New York, New York 10,021, USA. Phone: 646.962.2072; Email: [email protected].

MRI of Hepatocellular Carcinoma: Cross-regional Perspectives on Trends and Opportunities

Management of hepatocellular carcinoma (HCC) can vary substantially by region. The authors highlight differences between Eastern and Western health care systems in the use of MRI for surveillance, diagnosis, and treatment monitoring in patients with HCC. These regional differences reflect variations in disease prevalence, treatment practice patterns, and reimbursement policies as well as the evolving role of MRI in the care continuum, for which global consensus has not yet been achieved. Although variations are not uncommon, even within regions or countries, some general observations can be made and are represented by national or regional practice guidelines. For instance, in East Asia, where hepatitis B is the predominant cause of HCC and locoregional tumor ablation is preferred, guidelines emphasize high diagnostic sensitivity. Consequently, they employ broader screening criteria with MRI. Conversely, in Western regions where liver transplant for HCC is prioritized and the stakes for specificity are high, guidelines emphasize high pretest probabilities and stricter criteria for “definite HCC.” Although HCC diagnostic criteria remain somewhat divergent, the criteria for assessment of treatment response have transcended regional differences to evolve globally in tandem, shifting away from measuring the gross reduction in tumor size toward assessment based on features of tumor viability. This shift has been instrumental for adoption of immunotherapy, in which conventional size criteria may allow underestimation of its therapeutic benefit. Recognition of these regional variations is important in interpretation of multicenter international studies and to facilitate global collaboration in MRI-based management of HCC.

© RSNA, 2026

See the invited commentary by Ronot in this issue.

Newly discovered antiviral system in bacteria is ‘strangest of its kind’

Researchers at Gladstone Institutes have uncovered an unusual bacterial immune system that operates in reverse of known defenses. The discovery, published in Molecular Cell, details the mechanics of “type VI retrons”—a counterintuitive class of bacterial defenses. More than just a biological curiosity, decoding these complex systems provides a molecular blueprint that scientists can adapt to engineer more efficient DNA-editing tools for human health and therapies.

“This is, by far, the strangest of the retron systems that we or anyone else has come across,” says Gladstone investigator Seth Shipman, Ph.D., senior author of the new study. “These retrons operate with Rube Goldberg–level complexity, using molecular mechanisms that we would never have thought to invent, but that we’ll use in future technologies.”

Bacteria have long evolved specialized defenses to destroy phages, which are viruses that target bacterial cells. A line of defense, known as retrons, recognizes viral attacks and triggers self-destruction to protect the broader bacterial colony.

Opportunistic CT Screening: Clinical Applications, Technical Foundations, and Best Practices

Opportunistic CT screening refers to the extraction of clinically relevant imaging biomarkers from CT examinations routinely performed for unrelated primary indications. This screening does not require additional radiation exposure, imaging time, or patient burden. Advances in automated image analysis and artificial intelligence (AI) have substantially expanded the feasibility of opportunistic CT screening across a range of conditions, including low bone mineral density, hepatic steatosis, sarcopenia, adiposity, and vascular calcifications. These biomarkers are increasingly being recognized as important contributors to fracture risk, cardiometabolic disease, and frailty; yet they often remain undiagnosed in routine clinical practice. While numerous studies have demonstrated technical feasibility and diagnostic performance, widespread clinical adoption of opportunistic CT screening remains limited. Key challenges include those related to workflow integration, standardization of measurement techniques, quality assurance, interpretability of results, and uncertainty regarding downstream clinical management and value. In particular, not all opportunistic imaging biomarkers are equally actionable, and inappropriate or indiscriminate reporting may contribute to overdiagnosis or unnecessary follow-up. The authors summarize common applications of opportunistic CT screening, highlighting typical imaging findings and biomarkers. The authors discuss the evolution of automated and AI-based approaches, with emphasis on practical considerations for deployment, including pre-and postdeployment quality assurance, algorithm monitoring, and practical considerations for clinical integration. Emerging applications also are reviewed, with attention to current limitations. With a focus on clinical integration, this review is intended to inform radiologists, informaticians, and others working in health care systems who seek to translate opportunistic CT screening from proof-of-concept studies into scalable, clinically meaningful practice.

©RSNA, 2026

NASA’s SpaceX CRS-35 mission to launch health research

NASA experiments focused on human and plant health and drug-resistant organisms will travel to the International Space Station aboard SpaceX’s 35th Commercial Resupply Services mission for the agency from Cape Canaveral Space Force Station in Florida, advancing research that benefits life on Earth and future exploration.

This research supports astronaut health during long-duration missions through four investigations from the agency’s Biological and Physical Sciences division, including 3D models of the human brain, a crop disease study, a faster way to assess astronaut health and an analysis of antibiotic-resistant bacteria aboard the space station.

NASA Names Astronaut Christina Koch Acting Deputy Chief Engineer

NASA engineer and astronaut Christina Koch will serve as the agency’s acting deputy chief engineer beginning on Sunday, Nov. 1, following the retirement of Katherine Van Hooser, who will conclude more than 35 years of distinguished service to the agency on Wednesday, Oct. 21.

In her new role, Koch will help lead NASA’s engineering community, supporting technical oversight, mission readiness, and engineering excellence across the agency’s programs and projects. With this appointment, Koch will transition to management astronaut status and will no longer be eligible for future spaceflight assignments.

“Christina has seen NASA engineering from both sides of the equation: developing complex systems on the ground and trusting them with her life in space,” said NASA Administrator Jared Isaacman. “After spending nearly a year living and working aboard the International Space Station and helping lead America back around the Moon on Artemis II this year, she brings an extraordinary combination of technical expertise, operational experience, and judgment to this role. I am excited to see the impact she will have across NASA as we return Americans to the lunar surface, build the Moon Base, get underway on nuclear power in space, and develop the capabilities that will ultimately take us on to Mars.”

Planetary systems reveal two distinct families tied to their host stars

Analyzing a sample of 300 of the best-characterized planetary systems among the more than 1,000 known in the Milky Way, an international research team led by the Italian National Institute for Astrophysics (INAF) has discovered that the multiplanet systems identified so far belong to two distinct “families.”

The study, published in Nature Astronomy, demonstrates for the first time a true “genetic link” between the host star and its planets that shapes the birth, dynamical evolution and future stability of the entire planetary system.

/* */